Premier Alternatives

Pheon Therapeutics

United Kingdom · Founded 2015 · Privately Held (backing)

Developer of advanced cancer treatment intended for targeting hard-to-treat cancers. Pheon Therapeutics is based in United Kingdom and was founded in 2015. Its last known valuation is $173 million. It has raised $191 million.

Last price · $/share
—
Implied valuation
$172.7M
Total raised
$191.1M
Last round
—

Pheon Therapeutics key facts

  • Developer of advanced cancer treatment intended for targeting hard-to-treat cancers.
  • Pheon Therapeutics’s last known valuation is $172.7M.
  • It has raised $191.1M; the latest was Later Stage VC ($119.9M) in May 2024.
  • Notable investors include Lightspeed Venture Partners, Forbion, Perceptive Advisors, Hostplus Superannuation Fund, Atlas Venture — 11 tracked in total.
  • Status: Privately Held (backing).
Free account
More of Pheon Therapeutics with a free account
  • ·The complete investor list: 11 names
  • ·Watch Pheon Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Pheon Therapeutics funding rounds

No rounds on record

No funding rounds for Pheon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Pheon Therapeutics valuation

Pheon Therapeutics's last known valuation is $173 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

Pheon Therapeutics investors

11 investors are on record for Pheon Therapeutics, including Lightspeed Venture Partners, Forbion, Perceptive Advisors and Hostplus Superannuation Fund. By type, the record holds 3 venture capital firms, 1 hedge fund and 1 corporate investor.

About Pheon Therapeutics

Developer of advanced cancer treatment intended for targeting hard-to-treat cancers. The company leverages antibody drug conjugates to develop next-generation treatments, utilizing both novel and clinically validated monoclonal antibodies armed with proprietary payloads, enabling healthcare market to address unmet medical needs in solid tumors and liquid cancers through innovative and effective therapies.

Sector
Healthcare
HQ
United Kingdom
Founded
2015
Employees
29
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$172.7M

Pheon Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.